Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
27.2M
-
Number of holders
-
4
-
Total 13F shares, excl. options
-
463K
-
Shares change
-
-4.75M
-
Total reported value, excl. options
-
$12.4K
-
Value change
-
-$1.11M
-
Number of buys
-
2
-
Number of sells
-
-39
-
Price
-
$0.03
Significant Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS) as of Q1 2025
47 filings reported holding SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share as of Q1 2025.
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS) has 4 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 463K shares
of 27.2M outstanding shares and own 1.7% of the company stock.
Largest 10 shareholders include ACADIAN ASSET MANAGEMENT LLC (330K shares), Baader Bank Aktiengesellschaft (83.9K shares), 1492 Capital Management LLC (39.2K shares), XTX Topco Ltd (10.1K shares), BlackRock, Inc. (0 shares), Clarius Group, LLC (0 shares), SBI Securities Co., Ltd. (0 shares), PSI Advisors, LLC (0 shares), PNC Financial Services Group, Inc. (0 shares), and FNY Investment Advisers, LLC (0 shares).
This table shows the top 4 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.